JP2023521887A5 - - Google Patents
Info
- Publication number
- JP2023521887A5 JP2023521887A5 JP2022562668A JP2022562668A JP2023521887A5 JP 2023521887 A5 JP2023521887 A5 JP 2023521887A5 JP 2022562668 A JP2022562668 A JP 2022562668A JP 2022562668 A JP2022562668 A JP 2022562668A JP 2023521887 A5 JP2023521887 A5 JP 2023521887A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sustained
- pirfenidone
- composition according
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063010009P | 2020-04-14 | 2020-04-14 | |
| US63/010,009 | 2020-04-14 | ||
| PCT/US2021/027335 WO2021211745A1 (en) | 2020-04-14 | 2021-04-14 | Pirfenidone for coronavirus treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521887A JP2023521887A (ja) | 2023-05-25 |
| JP2023521887A5 true JP2023521887A5 (enExample) | 2024-04-25 |
Family
ID=78084909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562668A Pending JP2023521887A (ja) | 2020-04-14 | 2021-04-14 | コロナウイルス治療のためのピルフェニドン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230117397A1 (enExample) |
| EP (1) | EP4135671A4 (enExample) |
| JP (1) | JP2023521887A (enExample) |
| KR (1) | KR20230038644A (enExample) |
| CN (1) | CN115916162A (enExample) |
| AU (1) | AU2021254765A1 (enExample) |
| BR (1) | BR112022020821A2 (enExample) |
| CA (1) | CA3175526A1 (enExample) |
| CL (1) | CL2022002843A1 (enExample) |
| CO (1) | CO2022016155A2 (enExample) |
| EC (1) | ECSP22087664A (enExample) |
| IL (1) | IL297296A (enExample) |
| MX (1) | MX2022012986A (enExample) |
| WO (1) | WO2021211745A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| CN114796122B (zh) * | 2022-03-30 | 2023-03-24 | 山东大学 | 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用 |
| JP7845721B2 (ja) * | 2022-04-29 | 2026-04-14 | オーバーシーズ ファーマシューティカルズ リミテッド | ピルフェニドンの経口用持続放出性固形製剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU709178B2 (en) * | 1995-09-19 | 1999-08-26 | Intermune, Inc. | Inhibition of tumor necrosis factor alpha |
| US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
| WO2003030720A2 (en) * | 2001-10-09 | 2003-04-17 | The Children's Hospital Of Philadelphia | Materials and methods for preventing or reducing scar formation |
| US20070072181A1 (en) * | 2003-02-28 | 2007-03-29 | Blatt Lawrence M | Combination therapy for treating alphavirus infection and liver fibrosis |
| US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| MX2007014114A (es) * | 2005-05-10 | 2008-03-14 | Intermune Inc | Derivados de piridona para modular el sistema de proteina cinasa activada por estres. |
| NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| CN101088557A (zh) * | 2006-06-12 | 2007-12-19 | 天津市扶素生物技术有限公司 | 用于预防或治疗hiv感染的药用组合物及其应用 |
| US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| SG176053A1 (en) * | 2009-05-15 | 2011-12-29 | Intermune Inc | Methods of treating hiv patients with anti-fibrotics |
| CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
| ES2913095T3 (es) * | 2011-01-31 | 2022-05-31 | Avalyn Pharma Inc | Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| WO2013181691A1 (en) * | 2012-06-04 | 2013-12-12 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor |
| EP4491180A1 (en) * | 2014-01-10 | 2025-01-15 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
-
2021
- 2021-04-14 IL IL297296A patent/IL297296A/en unknown
- 2021-04-14 AU AU2021254765A patent/AU2021254765A1/en not_active Abandoned
- 2021-04-14 MX MX2022012986A patent/MX2022012986A/es unknown
- 2021-04-14 EP EP21788910.4A patent/EP4135671A4/en not_active Withdrawn
- 2021-04-14 BR BR112022020821A patent/BR112022020821A2/pt not_active Application Discontinuation
- 2021-04-14 WO PCT/US2021/027335 patent/WO2021211745A1/en not_active Ceased
- 2021-04-14 US US17/918,791 patent/US20230117397A1/en not_active Abandoned
- 2021-04-14 KR KR1020227039706A patent/KR20230038644A/ko active Pending
- 2021-04-14 JP JP2022562668A patent/JP2023521887A/ja active Pending
- 2021-04-14 CN CN202180042472.1A patent/CN115916162A/zh active Pending
- 2021-04-14 CA CA3175526A patent/CA3175526A1/en active Pending
-
2022
- 2022-10-14 CL CL2022002843A patent/CL2022002843A1/es unknown
- 2022-11-11 CO CONC2022/0016155A patent/CO2022016155A2/es unknown
- 2022-11-14 EC ECSENADI202287664A patent/ECSP22087664A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4041212B1 (en) | Mek inhibitors for the treatment of hantavirus infections | |
| JP2007506775A5 (enExample) | ||
| CN115916162A (zh) | 用于冠状病毒治疗的吡非尼酮 | |
| JP4627356B2 (ja) | ウイルス性心筋炎の予防または治療薬剤 | |
| JPWO2023054732A5 (enExample) | ||
| JP2026041886A5 (enExample) | ||
| JP2025508656A5 (enExample) | ||
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| EP2424893A2 (en) | Pharmaceutical agent | |
| JP2022540348A5 (enExample) | ||
| CA3190278A1 (en) | Antiviral use of liraglutide and gefitinib | |
| JP2023510965A5 (enExample) | ||
| CN115778944A (zh) | 蛇床子素在制备改善或治疗认知功能障碍的药物中的用途 | |
| CN113440614A (zh) | 一种用于治疗类风湿性关节炎的组合物及其应用 | |
| JP2025522146A5 (enExample) | ||
| CN107308121A (zh) | 肝脏再生的治疗剂 | |
| CA3152450C (en) | Mek inhibitors for the treatment of hantavirus infections | |
| US20240382510A1 (en) | New combination drug for treating coronavirus infections, pharmaceutical composition and use thereof | |
| US20100022576A1 (en) | Stable and bioavailable formulations and a novel form of desloratadine | |
| RU2498803C1 (ru) | Противотуберкулезное лекарственное средство | |
| JP4593953B2 (ja) | ライノウイルス感染症の予防薬 | |
| CN119055633A (zh) | 一类甲基麦冬黄酮a类衍生物在制备防治肝脏疾病药物中的应用 | |
| WO2025190943A1 (en) | Pharmaceutical composition comprising a fixed dose combination of ivermectin and albendazole | |
| CN118370758A (zh) | 托法替尼在制备治疗流感病毒感染的药物中的应用 | |
| RU2024124733A (ru) | Новые противовирусные фармацевтическая композиция, лекарственное средство ее содержащее, а также их применение для лечения и/или профилактики вирусных инфекций |